US Proposes Curbs on Investment in Chinese Biotech Firms
The Treasury Department proposed adding biotechnology to US outbound investment restrictions on China, covering equity deals, certain debt financing, joint ventures and fund investments in Chinese biotech firms. Conventional drug-licensing deals are generally spared. The proposal has a 45-day comment period, and Chinese biotech shares such as GenScript fell in Hong Kong.